108 related articles for article (PubMed ID: 22912356)
1. Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Cenci T; Martini M; Montano N; D'Alessandris QG; Falchetti ML; Annibali D; Savino M; Bianchi F; Pierconti F; Nasi S; Pallini R; Larocca LM
Am J Clin Pathol; 2012 Sep; 138(3):390-6. PubMed ID: 22912356
[TBL] [Abstract][Full Text] [Related]
2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
3. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
4. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
5. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.
Bommi PV; Dimri M; Sahasrabuddhe AA; Khandekar J; Dimri GP
Cell Cycle; 2010 Jul; 9(13):2663-73. PubMed ID: 20543557
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in the medical treatment of glioma-temozolomide].
Nishikawa R
No To Shinkei; 2006 Dec; 58(12):1035-41. PubMed ID: 17193953
[No Abstract] [Full Text] [Related]
7. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Pinel B; Duchesne M; Godet J; Milin S; Berger A; Wager M; Karayan-Tapon L
J Neurooncol; 2017 Apr; 132(2):287-294. PubMed ID: 28070830
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.
Xu F; Yang R; Wu L; He Q; Zhang Z; Zhang Q; Yang Y; Guo J; Chang C; Li X
Cancer Lett; 2012 Apr; 317(1):33-40. PubMed ID: 22120066
[TBL] [Abstract][Full Text] [Related]
10. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.
Bruggeman SW; Hulsman D; Tanger E; Buckle T; Blom M; Zevenhoven J; van Tellingen O; van Lohuizen M
Cancer Cell; 2007 Oct; 12(4):328-41. PubMed ID: 17936558
[TBL] [Abstract][Full Text] [Related]
11. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Jalali R
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1622; author reply 1622-3. PubMed ID: 19028293
[No Abstract] [Full Text] [Related]
12. Bmi1 and cell of origin determinants of brain tumor phenotype.
Dirks P
Cancer Cell; 2007 Oct; 12(4):295-7. PubMed ID: 17936553
[TBL] [Abstract][Full Text] [Related]
13. Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL.
van Galen JC; Muris JJ; Oudejans JJ; Vos W; Giroth CP; Ossenkoppele GJ; Otte AP; Raaphorst FM; Meijer CJ
J Clin Pathol; 2007 Feb; 60(2):167-72. PubMed ID: 16837630
[TBL] [Abstract][Full Text] [Related]
14. Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells.
Venugopal C; Li N; Wang X; Manoranjan B; Hawkins C; Gunnarsson T; Hollenberg R; Klurfan P; Murty N; Kwiecien J; Farrokhyar F; Provias JP; Wynder C; Singh SK
Stem Cell Res; 2012 Mar; 8(2):141-53. PubMed ID: 22265735
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
De Salvo M; Maresca G; D'agnano I; Marchese R; Stigliano A; Gagliassi R; Brunetti E; Raza GH; De Paula U; Bucci B
Int J Radiat Biol; 2011 May; 87(5):518-33. PubMed ID: 21405945
[TBL] [Abstract][Full Text] [Related]
16. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
17. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
18. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
[TBL] [Abstract][Full Text] [Related]
19. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
Combs SE; Gutwein S; Schulz-Ertner D; van Kampen M; Thilmann C; Edler L; Wannenmacher MM; Debus J
Strahlenther Onkol; 2005 Jun; 181(6):372-7. PubMed ID: 15925979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
